DEFA14A: TransCode Acquires Polynoma, Secures $25M Financing

TransCode Therapeutics announced the acquisition of Polynoma LLC and a concurrent $25 million strategic financing from a CK Life Sciences subsidiary, expanding its oncology pipeline with a Phase 3-ready asset.

Summary

• TransCode Therapeutics, Inc. (RNAZ) acquired 100% of the issued and outstanding membership interests of ABCJ, LLC (Polynoma LLC) from DEFJ, LLC, an indirect wholly-owned subsidiary of CK Life Sciences Intl., (Holdings) Inc.
• In exchange for Polynoma, TransCode issued DEFJ 83,285 shares of common stock (representing 9.99% of shares outstanding prior to closing) and 1,152.9568 shares of Series A Non-Voting Convertible Preferred Stock.
• TransCode agreed to make up to $95,000,000 in contingent milestone payments to DEFJ upon achievement of certain milestones for seviprotimut-L.
• Concurrently, DEFJ purchased 223.7337 shares of Series B Non-Voting Preferred Stock in a private placement for approximately $25 million, consisting of $20 million in cash and a $5 million promissory note due January 1, 2026.
• Each share of Series A and Series B Preferred Stock is convertible into 10,000 shares of Common Stock, subject to stockholder approval.
• Post-transaction, CK Life Sciences will hold approximately 91% and pre-acquisition TransCode stockholders approximately 9% of the combined fully diluted equity, with a combined fully diluted equity value of approximately $165 million.
• Existing TransCode stockholders of record as of October 20, 2025, will receive one contractual contingent value right (CVR) per share, entitling them to 50% of Net Proceeds from any upfront or milestone payments from a corporate partnering transaction of TTX-MC138.
• Philippe Calais, PharmD, PhD, was appointed Chief Executive Officer and remains Chairman of the Board. Thomas Fitzgerald transitioned from Interim CEO to Chief Financial Officer and Director.
• Elizabeth Czerepak, MBA, was appointed as a new independent Board Member and Chairperson of the Audit Committee, effective October 8, 2025.
• TransCode's Board unanimously approved the acquisition and financing, but stockholder approval is required for the conversion of Preferred Stock and a change of control under Nasdaq rules.

Sentiment

Score: 4

Explanation: While the acquisition of a Phase 3-ready asset and the associated financing provide a strategic expansion of the pipeline and funding for key programs, the substantial dilution for existing shareholders (91% to CK Life Sciences on a fully diluted basis) and the contingent nature of benefits like the CVR and milestone payments temper the immediate positive impact. The delay in filing complete financial statements for the acquired entity also adds a layer of uncertainty.

Positives

• Acquisition of Polynoma LLC expands the oncology pipeline with seviprotimut-L, a Phase 3-ready novel polyvalent shed antigen vaccine for adjuvant melanoma treatment.
• Secured $25 million in strategic financing from CK Life Sciences, providing capital primarily to advance TransCode's lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial.
• Potential for significant future contingent milestone payments of up to $95 million to DEFJ based on seviprotimut-L's clinical, regulatory, and commercial success.
• Existing TransCode stockholders will receive a non-transferrable Contingent Value Right (CVR) for potential future proceeds (50% of Net Proceeds) from a corporate partnering transaction of TTX-MC138.
• Strengthened management team with Dr. Philippe Calais appointed as Chief Executive Officer and the addition of Elizabeth Czerepak as an independent Board Member and Audit Committee Chairperson, bringing significant financial expertise.
• The combined entity aims to create a unique immuno-oncology and metastatic prevention oncology company, potentially realizing synergies between TTX-MC138 and seviprotimut-L technologies.

Negatives

• Significant dilution for pre-acquisition TransCode stockholders, who will hold approximately 9% of the combined fully diluted equity, while CK Life Sciences will hold approximately 91%.
• The $25 million financing includes a $5 million promissory note, not entirely immediate cash, which accrues interest at 4% per annum and is due on January 1, 2026.
• Conversion of the Series A and Series B Preferred Stock into Common Stock and approval of a change of control are subject to stockholder approval, which is not guaranteed and could impact the full realization of the transaction's structure.
• Financial statements for the acquired business and pro forma financial information are not immediately available and are expected to be filed by amendment within 71 days, leaving an incomplete financial picture.
• DEFJ, LLC retains a repurchase option for the acquired ABCJ interests under certain Triggering Events, introducing a potential risk of losing the acquired asset.

Risks

• Failure to obtain the Required Purchaser Stockholder Vote for the conversion of Preferred Stock and the change of control by December 31, 2026, could prevent full integration and impact Nasdaq listing compliance.
• The Company faces a risk of delisting from Nasdaq if the Purchaser Common Stock ceases to be listed for trading (other than in connection with an Optionee-approved Change of Control) prior to the third anniversary of the Closing Date.
• Contingent milestone payments of up to $95 million for seviprotimut-L are dependent on the successful achievement of specific clinical, regulatory, and commercial milestones, which are inherently uncertain.
• The Contingent Value Rights (CVRs) for existing stockholders are highly speculative, and there is no assurance that any payments will be received, as they depend on future corporate partnering of TTX-MC138.
• DEFJ, LLC holds a repurchase option for the acquired ABCJ interests, exercisable upon certain Triggering Events, including failure to dose the first patient in a seviprotimut-L Phase 3 clinical trial by the third anniversary of stockholder approval, Nasdaq delisting, or failure of the resale registration statement to become effective by June 30, 2026.
• The Company requires substantial additional capital for its operations and clinical development programs, as indicated in forward-looking statements.
• The effectiveness of the resale registration statement for shares issued to DEFJ is crucial, with a risk of a 'Registration Default' if it is not maintained, potentially triggering DEFJ's repurchase option.

Future Outlook

TransCode Therapeutics plans to advance its lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial, supported by the recent $25 million financing. The acquired seviprotimut-L, a Phase 3-ready asset, is expected to move towards a confirmatory Phase 3 trial (MELISSA). The company also intends to explore R&D combinations of TTX-MC138 and seviprotimut-L technologies and advance other preclinical candidates including TTX-siPDL1, TTX-RIGA, and TTX-siMYC. A proxy statement will be filed within 30 days of receiving required financial statements to seek stockholder approval for preferred stock conversion and change of control.

Management Comments

• "I am very honored to deepen my commitment and lead TransCode’s transformation into a one-of-a-kind leading oncology company at this critical time."
• "We are grateful for CK Life Sciences’ investment and their support of our miRNA candidate, TTX-MC138, as we now have the funding in place to fully execute our upcoming TTX-MC138 Phase 2."
• "This acquisition allows us to create a unique and broader pipeline with Phase 3 ready seviprotimut-L, and potentially realize synergies between both technologies, for the ultimate benefit of patients suffering from cancer and metastases."
• "Between the two programs, we see a unique potential to augment seviprotimut-L’s focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients."
• "Finally, I express my gratitude to Tom Fitzgerald for his remarkable dedication and commitment as he steps down from the Interim Chief Executive Officer position to revert to his previous role as Chief Financial Officer. I extend a warm welcome to all our new colleagues transitioning from Polynoma and to Elizabeth Czerepak, our new Independent Board member. All the ingredients are now in place to fully execute on our ambitious plan and deliver value to our shareholders."

Industry Context

This acquisition and financing position TransCode Therapeutics to expand its presence in the rapidly growing oncology market, particularly in immuno-oncology and metastatic cancer prevention, which is projected to reach $120-250 billion by 2032. By integrating Polynoma's Phase 3-ready seviprotimut-L vaccine with its proprietary TTX nanoparticle platform and microRNA-based therapeutics like TTX-MC138, TransCode aims to offer a diversified and potentially synergistic approach to cancer treatment. This move reflects a broader industry trend towards combination therapies and addressing the complex challenges of advanced disease and metastasis.

Comparison to Industry Standards

• Polynoma's seviprotimut-L is a novel polyvalent shed antigen vaccine for adjuvant treatment of Stage IIB and IIC melanoma patients. It has received FDA Orphan Drug status and Fast Track designation, and successfully completed an adaptive Phase 3 clinical trial (MAVIS).
• Seviprotimut-L is presented as a potentially safer and lower-cost alternative to existing checkpoint inhibitors (CPIs) like Keytruda (Merck) and Opdivo (BMS) for adjuvant melanoma treatment, which are known for severe, long-term side effects and limited patient response rates (<50%).
• TransCode's lead candidate, TTX-MC138, is a microRNA-10b targeted therapeutic, representing a distinct mechanism of action compared to traditional chemotherapy or broad-spectrum immunotherapies. Its Phase 0 results showed successful delivery to metastatic lesions and robust pharmacodynamic activity at microdoses.
• The company's strategy to explore combining TTX-MC138 and seviprotimut-L technologies suggests an innovative approach to potentially enhance treatment efficacy, particularly in addressing micrometastases in melanoma patients.

Management Changes

Corporate Governance

Related Party Transactions

• Acquisition of 100% of ABCJ, LLC (Polynoma) from DEFJ, LLC, which is an indirect wholly-owned subsidiary of CK Life Sciences Intl., (Holdings) Inc.
• Private placement of 223.7337 shares of Series B Non-Voting Preferred Stock to DEFJ, LLC for approximately $25 million ($20 million cash, $5 million promissory note).
• Contingent milestone payments of up to $95,000,000 from TransCode to DEFJ, LLC related to seviprotimut-L.
• Repurchase Agreement granting DEFJ, LLC the right to re-acquire ABCJ interests from TransCode under certain Triggering Events.
• DEFJ, LLC (as Seller) agreed to reimburse TransCode for up to $3,000,000 in "Reimbursable Expenses" incurred by OpCo between the Closing Date and December 31, 2025.
• One-time transaction bonus payments of $250,000 each to Dr. Philippe Calais (CEO) and Mr. Thomas Fitzgerald (CFO).
• Employment Agreement with Dr. Philippe Calais and adjusted annual base salary for Mr. Thomas Fitzgerald.

Stakeholder Impact

• Shareholders (Pre-acquisition): Experience significant dilution, with their ownership reduced to approximately 9% of the fully diluted equity. They receive Contingent Value Rights (CVRs) offering potential future proceeds from TTX-MC138 partnering, but these are highly speculative. Their approval is required for the conversion of preferred stock and change of control.
• CK Life Sciences Intl., (Holdings) Inc. / DEFJ, LLC: Becomes the dominant shareholder, holding approximately 91% of the fully diluted equity. Gains control over Polynoma's assets and a significant stake in TransCode, with substantial influence on the Board and strategic direction. Stands to receive contingent milestone payments.
• Employees: Polynoma employees are expected to transition to TransCode. Management roles are clarified with Dr. Calais as CEO and Mr. Fitzgerald as CFO, along with one-time transaction bonuses for both.
• Customers/Patients: The expanded pipeline, including the Phase 3-ready seviprotimut-L and the advancing TTX-MC138, offers potential new and diversified treatment options for metastatic cancer and melanoma, addressing unmet medical needs.

Next Steps

• TransCode will hold a stockholders meeting to seek approval for the conversion of Series A and B Preferred Stock into Common Stock and for a change of control under Nasdaq Listing Rules 5110 and 5635(b).
• A proxy statement on Schedule 14A will be filed with the SEC within 30 days following receipt of all required financial statements from the Seller.
• Financial statements for the acquired business and pro forma financial information are expected to be filed by amendment within 71 days after the 8-K filing date.
• TransCode is required to prepare and file a resale registration statement with the SEC within 75 calendar days following the closing of the Acquisition and Investment for shares issued to DEFJ.
• The company plans to advance its lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial.
• Preparations for the MELISSA Phase 3 confirmatory trial for seviprotimut-L are initiated.
• TransCode will use good faith efforts to authorize, nominate, and appoint a sixth director to the Purchaser Board by December 31, 2025.
• The company will explore R&D combinations of TTX-MC138 and seviprotimut-L technologies and advance other preclinical candidates (TTX-siPDL1, TTX-RIGA, TTX-siMYC).

Key Dates

Recommendation

The strategic acquisition of Polynoma and the associated $25 million financing significantly expand TransCode's pipeline with a Phase 3-ready asset and provide capital for its lead microRNA program. This could create long-term value by addressing critical needs in oncology. However, the substantial dilution for existing shareholders (91% to the new strategic investor on a fully diluted basis) and the contingent nature of some benefits (CVR, milestone payments) introduce considerable risk and uncertainty. The requirement for stockholder approval for preferred stock conversion and change of control, along with the delayed financial statements for the acquired entity, further contribute to a mixed outlook. A 'hold' recommendation is appropriate as investors should monitor the integration of Polynoma, progress in clinical trials, and the outcome of the stockholder vote before making further investment decisions.

Keywords

TransCode Therapeutics, RNAZ, Polynoma, acquisition, strategic financing, immuno-oncology, metastatic cancer, seviprotimut-L, TTX-MC138, microRNA, cancer vaccine, Nasdaq, preferred stock, contingent value rights, corporate governance, CEO, CFO, board appointment, clinical trials, drug development, biotechnology